These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16465841)

  • 41. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
    Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
    Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statins and hypertension.
    Cífková R; Nilsson PM
    J Hypertens; 2009 Mar; 27(3):662-5. PubMed ID: 19262236
    [No Abstract]   [Full Text] [Related]  

  • 43. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 44. [For prevention of cardiovascular diseases: statins in old age?].
    MMW Fortschr Med; 2006 Sep; 148(38):16. PubMed ID: 17036955
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
    Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
    J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ENHANCE: food for the ostriches.
    Jackson G
    Int J Clin Pract; 2008 May; 62(5):667-8. PubMed ID: 18412925
    [No Abstract]   [Full Text] [Related]  

  • 47. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [LDL lowering--level and time. Maybe two equally important parameters for protection against arteriosclerosis].
    Herlitz J
    Lakartidningen; 2006 Oct 25-31; 103(43):3272-3. PubMed ID: 17117658
    [No Abstract]   [Full Text] [Related]  

  • 50. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
    Puccetti L; Pasqui AL; Bruni F; Pastorelli M; Ciani F; Palazzuoli A; Pontani A; Ghezzi A; Auteri A
    Int J Cardiol; 2007 Jun; 119(1):41-7. PubMed ID: 17050011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 52. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE).
    Johnson KR; Freemantle N; Anthony DM; Lassere MN
    J Clin Epidemiol; 2009 Mar; 62(3):328-36. PubMed ID: 18834708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Diabetes Res Clin Pract; 2009 May; 84(2):e33-7. PubMed ID: 19243852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Dual lipid control without anti-atherosclerosis effect].
    Einecke D
    MMW Fortschr Med; 2008 Apr; 150(16):18, 20. PubMed ID: 18557109
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Almonds have a neutral effect on serum lipid profiles: a meta-analysis of randomized trials.
    Phung OJ; Makanji SS; White CM; Coleman CI
    J Am Diet Assoc; 2009 May; 109(5):865-73. PubMed ID: 19394473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.